ImmunoGen, Inc. , a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced the presentation of encouraging clinical findings with its IMGN529 experimental therapy for B-cell malignancies at the American Society of Hematology annual meeting . These include objective responses at doses that were generally well tolerated.
http://ift.tt/1AWOTck
http://ift.tt/1AWOTck
No comments:
Post a Comment